Rallybio (NASDAQ:RLYB) Announces Quarterly Earnings Results

Rallybio (NASDAQ:RLYB) issued its quarterly earnings data on Thursday. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.02, Zacks reports.

Rallybio Stock Performance

RLYB opened at $0.66 on Thursday. The firm’s 50-day simple moving average is $0.83 and its 200-day simple moving average is $0.98. The firm has a market cap of $27.34 million, a price-to-earnings ratio of -0.41 and a beta of -1.45. Rallybio has a twelve month low of $0.62 and a twelve month high of $3.46.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price target on shares of Rallybio in a research report on Wednesday, February 12th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $9.75.

About Rallybio

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.